(-0.03%) 5 330.25 points
(-0.01%) 39 939 points
(-0.15%) 18 735 points
(-0.86%) $79.11
(0.22%) $2.76
(-0.81%) $2 418.80
(-2.02%) $31.77
(-1.73%) $1 045.30
(-0.10%) $0.920
(-0.41%) $10.65
(-0.12%) $0.786
(-0.34%) $90.37
@ $0.657
发出时间: 15 Feb 2024 @ 04:30
回报率: 192.46%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 6.16 %
Live Chart Being Loaded With Signals
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...
Stats | |
---|---|
今日成交量 | 3.50M |
平均成交量 | 9.85M |
市值 | 494.07M |
EPS | $0 ( 2024-05-14 ) |
下一个收益日期 | ( $-0.0600 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.35 |
ATR14 | $0.00800 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.74 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
音量 相关性
Ocugen Inc 相关性 - 货币/商品
Ocugen Inc 财务报表
Annual | 2023 |
营收: | $6.04M |
毛利润: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2023 |
营收: | $6.04M |
毛利润: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.07M (0.00 %) |
EPS: | $-0.360 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。